BioArctic Faces Novartis Exit, OMXS30 Removal Amid Ongoing Neuro‑Degenerative Trials
BioArctic faces Novartis exit, OMXS30 removal, but still pushes Alzheimer’s and Parkinson’s therapies forward—what this means for investors and research.
3 minutes to read
